Literature DB >> 23731601

Virus-induced humoral immunity: on how B cell responses are initiated.

Franziska Zabel1, Thomas M Kündig, Martin F Bachmann.   

Abstract

Most antiviral vaccines are based on viral particles, which are efficient inducers of B cell responses. In addition to their ability to replicate, several features associated with the structure and content of the viral particles are responsible for this high immunogenicity. First, viral particles usually have dimensions between 20 and 200 nm, a size optimal for drainage to lymph nodes and direct interaction with B cells. Second, the surface of most viral particles is highly repetitive, causing efficient cross-linking of B cell receptors, an early and key step of B cell activation. In addition, such repetitive structures bind natural antibodies and fix complement, further enhancing B cell activation as well as transport to and deposition on follicular dendritic cells. Third, viral particles carry ligands for toll-like receptor 7/8 or 9 which activate B cells directly for isotype switching as well as dendritic cells for T cell priming. In this review, we will highlight recent insights in these mechanisms and discuss their impact on antiviral antibody responses.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23731601     DOI: 10.1016/j.coviro.2013.05.004

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  35 in total

1.  M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection.

Authors:  Wenqian Tao; Harvinder S Gill
Journal:  Vaccine       Date:  2015-04-02       Impact factor: 3.641

2.  Safety and immunogenicity of influenza whole inactivated virus vaccines: A phase I randomized clinical trial.

Authors:  Renée A J van Boxtel; Pauline Verdijk; Otto J de Boer; Elly van Riet; Tjeert T Mensinga; Willem Luytjes
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 3.  Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platform.

Authors:  John P O'Rourke; David S Peabody; Bryce Chackerian
Journal:  Curr Opin Virol       Date:  2015-03-29       Impact factor: 7.090

Review 4.  A Special Connection between γδ T Cells and Natural Antibodies?

Authors:  Willi K Born; Yafei Huang; Wanjiang Zeng; Raul M Torres; Rebecca L O'Brien
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2016-05-27       Impact factor: 4.291

Review 5.  Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases.

Authors:  Pan Tao; Jingen Zhu; Marthandan Mahalingam; Himanshu Batra; Venigalla B Rao
Journal:  Adv Drug Deliv Rev       Date:  2018-07-06       Impact factor: 15.470

Review 6.  Natural Killer Cell Regulation of B Cell Responses in the Context of Viral Infection.

Authors:  Ivayla E Gyurova; Ayad Ali; Stephen N Waggoner
Journal:  Viral Immunol       Date:  2019-12-03       Impact factor: 2.257

Review 7.  Adjuvant formulations for virus-like particle (VLP) based vaccines.

Authors:  Velasco Cimica; Jose M Galarza
Journal:  Clin Immunol       Date:  2017-08-03       Impact factor: 3.969

8.  Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.

Authors:  Wenqian Tao; Brett L Hurst; Akhilesh Kumar Shakya; Md Jasim Uddin; Rohan S J Ingrole; Mayra Hernandez-Sanabria; Ravi P Arya; Lynn Bimler; Silke Paust; E Bart Tarbet; Harvinder Singh Gill
Journal:  Antiviral Res       Date:  2017-02-02       Impact factor: 5.970

9.  Activation and measurement of NLRP3 inflammasome activity using IL-1β in human monocyte-derived dendritic cells.

Authors:  Melissa V Fernandez; Elizabeth A Miller; Nina Bhardwaj
Journal:  J Vis Exp       Date:  2014-05-22       Impact factor: 1.355

Review 10.  Engineering virus-like particles as vaccine platforms.

Authors:  Kathryn M Frietze; David S Peabody; Bryce Chackerian
Journal:  Curr Opin Virol       Date:  2016-03-29       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.